Drugs / procarbazine
procarbazine
also known as
procarbazine hydrochloride · Ibenzmethyzine hydrochloride · Matulane · Natulan · NCI-C 01810 · NSC-77213 · PCB · Procarbacine · +8 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MATULANE | — | 1969-07-22 | fda.gov ↗ |
Trials 64 · started per year
today
US approved 1969
2
1
1
3
4
7
3
5
5
4
1
2
5
4
2
1
1
2
1
2
1
1
2
1
1968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00734773 | Nov 2008 → ? | central nervous system neoplasm, lymphoma | Northwestern University | Withdrawn | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT00005796 | Feb 2000 → Jun 2003 | bone marrow disorder, central nervous system neoplasm, chemotherapy-induced toxicity | Indiana University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004004 | Jul 1999 → Aug 2003 | central nervous system neoplasm | New Approaches to Brain Tumor Therapy Consortium | Completed | No outcome recorded |
| Phase 231 trials | ||||||
| Phase 2 | NCT05008224 | Oct 2021 → Oct 2023 | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT05425654 | May 2021 → May 2023 | primary central nervous system lymphoma | National Research Center for Hematology, Russia | Unknown | No outcome recorded |
| Phase 2 | NCT03495960 | Jun 2019 → Dec 2024 | primary central nervous system lymphoma | International Extranodal Lymphoma Study Group (IELSG) | Completed | No outcome recorded |
| Phase 2 | NCT01775475 | Sep 2016 → Apr 2021 | diffuse large B-cell lymphoma, large-cell immunoblastic lymphoma, precursor lymphoblastic lymphoma/leukemia | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 2 | NCT01390584 | May 2013 → Apr 2015 | lymphoma | ECOG-ACRIN Cancer Research Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01737346 | Oct 2012 → Sep 2013 | glioblastoma | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01118026 | Sep 2010 → Sep 2020 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT01132807 | May 2010 → Feb 2016 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT01124240 | Nov 2009 → Nov 2012 | glioblastoma | Northern Sydney and Central Coast Area Health Service | Unknown | No outcome recorded |
| Phase 2 | NCT00989352 | Sep 2009 → Jun 2011 | primary central nervous system lymphoma | University Hospital Freiburg | Unknown | No outcome recorded |
| Phase 2 | NCT00822120 | Jul 2009 → Apr 2016 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00795613 | Jun 2008 → Nov 2014 | Hodgkins lymphoma | Ospedale Santa Croce-Carle Cuneo | Unknown | No outcome recorded |
| Phase 2 | NCT00666484 | Mar 2008 → Sep 2012 | lymphoma, poisoning | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT00574496 | Nov 2007 → Aug 2022 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00335140 | Aug 2007 → Jul 2015 | lymphoma | Eastern Cooperative Oncology Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00151281 | Nov 2004 → Dec 2009 | non-Hodgkin lymphoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT01468740 | Mar 2004 → Feb 2012 | Hodgkins lymphoma | Harlachinger Krebshilfe e.V. | Unknown | No outcome recorded |
| Phase 2 | NCT00079092 | Jan 2004 → Mar 2006 | central nervous system neoplasm | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00284271 | Jan 2004 → Dec 2005 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT00416832 | Nov 2002 → Dec 2005 | lymphoma | Christine Mauz-Körholz | Completed | No outcome recorded |
| Phase 2 | NCT00025064 | Jan 2000 → ? | lymphoma | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 2 | NCT00074191 | Jan → Oct 2000 | lymphoma | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00004010 | Oct 1999 → Oct 2003 | lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00003929 | Jun 1998 → Mar 2000 | lymphoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00049439 | Mar 1998 → Oct 2005 | lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003101 | Aug 1997 → Jan 2002 | central nervous system neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003114 | Jul 1997 → Jun 2002 | lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003113 | Jul 1997 → Dec 2002 | lymphoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00002806 | Jul 1996 → Jan 2003 | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00592111 | Mar 1996 → Feb 1999 | Hodgkins lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002463 | Feb 1989 → Jan 2007 | central nervous system neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00003375 | Oct 1998 → Aug 2005 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | Met primary |
| Phase 321 trials · 3 met primary · 6 missed | ||||||
| Phase 3 | NCT05675410 | May 2023 → Apr 2031 expected | Hodgkins lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT03632135 | May 2018 → Jun 2022 | glioblastoma | Cordgenics, LLC | Completed | Met primary |
| Phase 3 | NCT01652261 | May 2013 → Oct 2014 | Hodgkins lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00887146 | Sep 2009 → Oct 2029 expected | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00678327 | Aug 2008 → Jan 2016 | lymphoma | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT00515554 | May 2008 → Jul 2019 | Hodgkins lymphoma | University of Cologne | Completed | Mixed |
| Phase 3 | NCT00433433 | Oct 2006 → Dec 2011 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | Missed primary |
| Phase 3 | NCT00052455 | Oct 2002 → Sep 2010 | central nervous system cancer | Institute of Cancer Research, United Kingdom | Completed | Missed primary |
| Phase 3 | NCT00049595 | Aug 2002 → Jan 2010 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Missed primary |
| Phase 3 | NCT01251107 | Mar 2000 → Nov 2009 | Hodgkins lymphoma | Fondazione Michelangelo | Completed | No outcome recorded |
| Phase 3 | NCT00265031 | Jan 1999 → ? | Hodgkins lymphoma | University of Cologne | Completed | Mixed |
| Phase 3 | NCT00005584 | Oct 1998 → May 2004 overdue | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | Mixed |
| Phase 3 | NCT00003421 | Jun 1998 → Nov 2005 | lymphoma | Medical Research Council | Completed | Missed primary |
| Phase 3 | NCT00264953 | May 1998 → Jan 2003 | Hodgkins lymphoma | University of Cologne | Completed | Mixed |
| Phase 3 | NCT00003293 | Feb 1998 → May 2001 | central nervous system neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00002944 | Apr 1997 → Feb 2006 | brain neoplasm | Children's Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00002840 | Aug 1996 → Mar 2002 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Met primary |
| Phase 3 | NCT00002569 | Jul 1994 → Feb 2005 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00379041 | Sep 1993 → Oct 1998 overdue | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | Met primary |
| Phase 3 | NCT00002462 | Sep 1989 → May 2000 overdue | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00003564 | — | central nervous system cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00188149 | May 2000 → Dec 2007 | Hodgkins lymphoma | University Hospital Carl Gustav Carus | Unknown | No outcome recorded |
| Phase not applicable7 trials · 1 missed | ||||||
| — | NCT02800447 | Jun 2016 → Dec 2018 | Hodgkins lymphoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| — | NCT02333513 | Feb 2015 → Dec 2017 | malignant glioma | Hebei Yanda Hospital | Unknown | No outcome recorded |
| — | NCT01304849 | Jan 2011 → Sep 2013 | Hodgkins lymphoma | Cancer Institute WIA | Completed | Missed primary |
| — | NCT00187057 | Sep 2002 → Aug 2006 | ataxia telangiectasia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| — | NCT00594815 | Aug 2002 → Feb 2016 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00416377 | — | lymphoma | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| — | NCT00417014 | — | lymphoma | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Comparator or background therapy20 trials | ||||||
| Phase 1 | NCT06541665 Background | May 2024 → Apr 2028 expected | primary central nervous system lymphoma | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03576378 Background | Aug 2018 → Oct 2023 | Hodgkins lymphoma | Spanish Lymphoma Cooperative Group | Unknown | No outcome recorded |
| Phase 1/2 | NCT02315326 Background | Dec 2014 → Jan 2026 | central nervous system non-hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT07015242 Background | Nov 2025 → Jan 2028 expected | lymphoma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 2 | NCT02298283 Background | Apr 2015 → Jul 2020 | Hodgkins lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2 | NCT01569204 Comparator | Oct 2012 → Mar 2014 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT01399372 Background | Sep 2011 → Mar 2020 | chemotherapy-induced toxicity, cognitive disorder, lymphoma, radiation-induced disorder | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00503594 Comparator | Jul 2007 → Jul 2010 | lymphoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT00079105 Comparator | Jan 2004 → Dec 2010 | lymphoma | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT00431561 Comparator | Apr 2003 → Mar 2009 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Completed | No outcome recorded |
| Phase 3 | NCT06830421 Comparator | Aug 2023 → Aug 2029 expected | primary central nervous system lymphoma | University Hospital Freiburg | Recruiting | No outcome recorded |
| Phase 3 | NCT04702581 Background | Dec 2021 → Dec 2030 expected | oligodendroglioma | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 3 | NCT05331521 Comparator | Apr 2021 → Mar 2033 expected | oligodendroglioma | University Hospital Heidelberg | Recruiting | No outcome recorded |
| Phase 3 | NCT02661503 Comparator | Jul 2016 → Dec 2022 | classic Hodgkin lymphoma | University of Cologne | Unknown | Met primary |
| Phase 3 | NCT02444000 Background | Sep 2015 → Oct 2022 | malignant glioma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01356680 Background | Jan 2012 → Mar 2020 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT01358747 Comparator | May 2011 → ? | Hodgkins lymphoma | Centre Hospitalier Universitaire Dijon | Completed | Met primary |
| Phase 3 | NCT00433459 Comparator | Jan 2007 → Jan 2013 | lymphoma | Christine Mauz-Körholz | Completed | Mixed |
| Phase 3 | NCT00003788 Background | Apr 1998 → ? | central nervous system cancer | Colorado Health Foundation | Unknown | No outcome recorded |
| Phase 3 | NCT00577993 Comparator | Mar 1998 → Aug 2017 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-01 | Pfizer | Results Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma pfizer.com ↗
The four-year analysis presented by the GHSG showed superior progression-free survival (PFS) and improved tolerability for patients compared to a current standard of care regimen used in Europe in this setting. |
| 2022-05-20 | Lee's Pharmaceutical Limited | Regulatory New product Natulan® obtained Drug Registration Certificate leespharm.com ↗
Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, the Drug Registration Certificate for in-licensed product Natulan® (Procarbazine Capsules) has been obtained from the China National Medical Products Administration (“NMPA”). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-01 | Pfizer | Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma pfizer.com ↗ |
| 2023-05-02 | Lee's Pharmaceutical Limited | In-licensed product Natulan® (Procarbazine Hydrochloride Capsules) was successfully launched in China leespharm.com ↗ |
| 2022-05-20 | Lee's Pharmaceutical Limited | New product Natulan® obtained Drug Registration Certificate leespharm.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 85 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Procarbazine | “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Carboplatin;
* Irinotecan;
* Etoposide;
*...” NCT03632135 ↗75“bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4...” NCT01118026 ↗ “BACOPP-D regimen which includes cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine” NCT00188149 ↗ “temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen” NCT00431561 ↗ “bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc)” NCT01652261 ↗ “Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14°” NCT00795613 ↗ “cyclophosphamide, procarbazine, etoposide and prednisone (BEACOPP)” PMID 28601705 ↗ Jun 2017 “Days 8-21: Procarbazine 60 mg/m2 orally (capped at 100 mg).” NCT05331521 ↗ “plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5” NCT03576378 ↗ “Prednisone, Cyclophosphamide, Etoposide, Procarbazine” NCT00151281 ↗ “Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO” NCT01304849 ↗ |
| Known as | Ibenzmethyzine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | Matulane | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | Natulan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02800447 ↗ |
| Known as | NCI-C 01810 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | NSC-77213 | “Procarbazine, PCB, NSC-77213” NCT00002462 ↗ |
| Known as | PCB | “Procarbazine, PCB, NSC-77213” NCT00002462 ↗ |
| Known as | Procarbacine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00284271 ↗ |
| Known as | Procarbazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | Procarbazine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | procarbazine hydrochloride | “Drug: Procarbazine Hydrochloride” NCT00002463 ↗13“Drug: procarbazine hydrochloride” NCT00049595 ↗ “Drug: procarbazine hydrochloride” NCT00666484 ↗ “Drug: procarbazine hydrochloride” NCT00079105 ↗ “Drug: procarbazine hydrochloride” NCT00678327 ↗ “Drug: procarbazine hydrochloride” NCT00003375 ↗ “Drug: procarbazine hydrochloride” NCT00002569 ↗ “procarbazine hydrochloride” NCT00002840 ↗ |
| Known as | Procarbazini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO 4 6467/1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO 4-646711 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO-4-6467 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO-4-6467 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Known as | RO-4-6467 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1321 ↗ |
| Modality | Small molecule | — CHEMBL1321 ↗ |
| Route | Oral | “oral procarbazine and oral prednisone on days 1-10” NCT00002463 ↗ |